Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * * *
NEWS				Web Page for STN Seminar Schedule - N. America
NEWS				CA/CAplus patent coverage enhanced
NEWS	3	JUL	28	EPFULL enhanced with additional legal status
				information from the epoline Register
NEWS		JUL		IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS		JUL		STN Viewer performance improved
NEWS		AUG		INPADOCDB and INPAFAMDB coverage enhanced
NEWS		AUG		CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS				CAOLD to be discontinued on December 31, 2008
NEWS		AUG		CAplus currency for Korean patents enhanced
NEWS	10	AUG	27	CAS definition of basic patents expanded to ensure
				comprehensive access to substance and sequence
				information
NEWS	11	SEP	18	Support for STN Express, Versions 6.01 and earlier,
			0.5	to be discontinued
NEWS	12	SEP	25	CA/CAplus current-awareness alert options enhanced
				to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP	26	WPIDS, WPINDEX, and WPIX coverage of Chinese and
NEWS	13	SEP	20	and Korean patents enhanced
NEWS	1.4	SEP	29	IFICLS enhanced with new super search field
NEWS		SEP		EMBASE and EMBAL enhanced with new search and
HEND	10	OHL	23	display fields
NEWS	16	SEP	30	CAS patent coverage enhanced to include exemplified
				prophetic substances identified in new Japanese-
				language patents
NEWS	17	OCT	07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT	07	Multiple databases enhanced for more flexible patent
				number searching
NEWS	19	OCT	22	Current-awareness alert (SDI) setup and editing
				enhanced
NEWS	20	OCT	22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
				Applications
NEWS	21	OCT	24	CHEMLIST enhanced with intermediate list of
				pre-registered REACH substances
MINITO			*****	
NEWS	EXP	RESS		E 27 08 CURRENT WINDOWS VERSION IS V8.3,
			AND	CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:08:42 ON 13 NOV 2008

=> file reg COST IN U.S. DOLLARS

COST IN U.S. DOLLARS FULL ESTIMATED COST SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FILE 'REGISTRY' ENTERED AT 18:08:51 ON 13 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR SIN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2008 HIGHEST RN 1072189-85-5 DICTIONARY FILE UPDATES: 12 NOV 2008 HIGHEST RN 1072189-85-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\512.str

L1 STRUCTURE UPLOADED

-> e 11

SAMPLE SEARCH INITIATED 18:12:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 491 TO ITERATE

100.0% PROCESSED 491 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE** PROJECTED ITERATIONS:

8491 TO 11149 80

PROJECTED ANSWERS:

1 TO

L2

1 SEA SSS SAM L1

=> s 11 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y) /N or END:v FULL SEARCH INITIATED 18:12:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9531 TO ITERATE

100.0% PROCESSED 9531 ITERATIONS SEARCH TIME: 00.00.01

46 ANSWERS

1 ANSWERS

46 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 180.66 180.87

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 18:12:39 ON 13 NOV 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2008 VOL 149 ISS 20 FILE LAST UPDATED: 12 Nov 2008 (20081112/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

2 L3

=> s 14 and agejas-chicharro, f?/au 3 AGEJAS-CHICHARRO, F?/AU

L5 1 L4 AND AGEJAS-CHICHARRO, F?/AU

=> d 15, ibib abs hitstr, 1

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1103576 HCAPLUS

DOCUMENT NUMBER: 143:386923

TITLE: Preparation of pyridines as mGlu5 receptor antagonists

INVENTOR(S): Agejas-Chicharro, Francisco Javier;

Dressman, Bruce Anthony; Gutierrez Sanfeliciano,

Sonia; Henry, Steven Scott; Martinez Perez, Jose Antonio; Massey, Steven Marc; Monn, James Allen;

Zia-Ebrahimi, Mohammad Sadegh Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT ASSIGNEE(S):

PAT	PATENT NO.				KIND DATE			APPLICATION NO.					DATE					
WO	WO 2005094822				A1 20051013			WO 2005-US7507				20050309						
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
							DE,											
							ID,											
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NΙ,	
		NO,	ΝZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	
		SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	zw
	RW:	BW,	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
		ΑZ,	ΒY,	KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,	
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	
					TD,													
EP	EP 1729771			A1 20061213			EP 2005-724939											
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	ΗU,	ΙE,	
							MC,											
US	US 20080194647				A1 20080814 US 2006-598512 20060													
PRIORITY	PRIORITY APPLN. INFO.:									US 2	004-	5551	37P		P 2	0040	322	
WO 2005-US7507 W						W 2	0050	309										
OTHER SO					CASREACT 143:386923; MARPAT 143:386923													

- AB The invention is related to compds. I [Ar = (un)substituted Ph, naphthyl; Rl = H, halo, CN, CF3, CO2H and derives, etc.; R2 = 1,2-ethenediyl, 1,2-ethynediyl], their pharmaceutically acceptable salts, and N-oxides as antagoniets of the metabotropic glutamate (mGlu), particularly mGlu5, receptors (no data). I may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor (no data). The invention is also related to the preparation of pyridines I provided they are other than 5-(phenylethynyl)nicotinonitrile. For example, II was prepared, in 56% yield, by Pd-coupling of 3,4-difluoroiodobenzeme with 5-ethynylnicotinonitrile. II may be particularly useful for the treatment of anxiety and/or pain.
- IT 866683-66-1P, 5-(4-Fluoro-3
 - hydroxymethylphenylethynyl)nicotinonitrile 866685-84-9P, 5-(5-Cyanopyridin-3-ylethynyl)-2-fluorobenzoic acid 866685-88-3P, 5-(5-Cyanopyridin-3-ylethynyl)-2-fluorobenzoic acid methyl ester 86686-19-3P, [5-(5-Cyanopyridin-3-ylethynyl)-2-fluorobenzyl]carbamic acid tert-butyl ester 86686-50-2P, 5-(3-Amino-4-fluorophenylethynyl)nicotinonitrile RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); TBU (Therapeutic use); BTOL (Biological study); PREP
- (drug candidate; preparation of pyridines as mGlu5 receptor antagonists) RN 866683-66-1 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-[4-fluoro-3-(hydroxymethyl)phenyl]ethynyl]-(CA INDEX NAME)

(Preparation); RACT (Reactant or reagent); USES (Uses)

- RN 866685-84-9 HCAPLUS
- CN Benzoic acid, 5-[2-(5-cyano-3-pyridiny1)ethyny1]-2-fluoro- (CA INDEX NAME)

RN 866685-88-3 HCAPLUS

CN Benzoic acid, 5-[2-(5-cyano-3-pyridinyl)ethynyl]-2-fluoro-, methyl ester (CA INDEX NAME)

RN 866686-19-3 HCAPLUS

CN Carbamic acid, [[5-[(5-cyano-3-pyridinyl)ethynyl]-2-fluorophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 866686-50-2 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(3-amino-4-fluorophenyl)ethynyl]- (CA INDEX NAME)

IT 866684-05-1P, 5-(2-Chlorophenylethynyl)nicotinonitrile 866684-07-3P, 5-(3-Chlorophenylethynyl)nicotinonitrile 866684-08-4P, 5-(2-Fluorophenylethynyl)nicotinonitrile 866684-10-8P, 5-(3-Fluorophenylethynyl)nicotinonitrile

```
866684-12-0P, 5-(4-Fluorophenylethynyl)nicotinonitrile
866684-45-9P, 5-(4-Chlorophenylethynyl)nicotinonitrile
866684-85-7P, 5-(3,4-Difluorophenylethynyl)nicotinonitrile
866684-87-9P, 5-(3,5-Difluorophenylethynyl)nicotinonitrile
866684-88-0P, 5-(3,4,5-Trifluorophenylethynyl)nicotinonitrile
866685-08-7P, 5-(3-Chloro-4-fluorophenylethynyl)nicotinonitrile
866685-14-5P, 5-(5-Chloro-2-methoxyphenylethynyl)nicotinonitrile
866685-16-7P, 5-(3-Chloro-4-methoxyphenylethynyl)nicotinonitrile
866685-17-8P, 5-(3-Hydroxy-4-fluorophenylethynyl)nicotinonitrile
866685-19-0P, 5-(4-Fluoro-3-methoxyphenylethynyl)nicotinonitrile
866685-20-3P, 5-(4-Fluoro-3-ethoxyphenylethynyl)nicotinonitrile
866685-22-5P, 5-(4-Fluoro-3-
isopropoxyphenylethynyl)nicotinonitrile 866685-82-7P,
5-(5-Cvanopyridin-3-vlethynyl)-2-fluorobenzamide 866685-85-0P,
5-(5-Cyanopyridin-3-ylethynyl)-2-fluoro-N-methylbenzamide
866685-87-2P, 5-(5-Cyanopyridin-3-ylethynyl)-2-fluoro-N, N-
dimethylbenzamide 866686-16-0P,
N-[5-(5-Cyanopyridin-3-ylethynyl)-2-fluorobenzyl]acetamide
866686-17-1P, 5-(3-Aminomethyl-4-
fluorophenylethynyl)nicotinonitrile 866686-20-6P,
5-[[3-](Dimethylamino)methyl]-4-fluorophenyl]ethynyl]nicotinonitrile
866686-22-8P, 5-(3-Cvanomethyl-4-
fluorophenylethynyl)nicotinonitrile 866686-24-0P.
N-[5-(5-Cyanopyridin-3-ylethynyl)-2-fluorobenzyl]methanesulfonamide
866686-25-1P, 5-[[3-[[(2-Cvanoethyl)(methyl)amino]methyl]-4-
fluorophenvl]ethvnvl]nicotinonitrile 866686-27-3P,
5-[[4-Fluoro-3-[[(isopropyl)(methyl)amino]methyl]phenyl]ethynyl]nicotinoni
trile 866686-28-4P, 5-[[4-Fluoro-3-
[(isopropylamino)methyl]phenyl]ethynyl]nicotinonitrile
866686-30-8P, 5-[[4-Fluoro-3-
[(propylamino)methyl]phenyl]ethynyl]nicotinonitrile 866686-31-9P
, 5-[[4-Fluoro-3-[(ethylamino)methyl]phenyl]ethynyl]nicotinonitrile
866686-33-1P, 5-[[4-Fluoro-3-
[(methylamino)methyl]phenyl]ethynyl]nicotinonitrile 866686-38-6P
, [5-(5-Cyanopyridin-3-ylethynyl)-2-fluorobenzyl]carbamic acid ethyl ester
866686-49-9P, N-[5-(5-Cyanopyridin-3-ylethynyl)-2-
fluorophenyl]isobutyramide 866686-52-4P,
5-(4-Fluoro-3-nitrophenylethynyl)nicotinonitrile 866687-15-2P,
5-(3-Cvano-4-fluorophenylethynyl)nicotinonitrile 866687-21-0P,
N-[5-(5-Cvanopyridin-3-ylethynyl)-2-fluorophenyl]acetamide
866687-23-2P, N-[5-(5-Cyanopyridin-3-ylethynyl)-2-
fluorophenyl]methanesulfonamide 866687-24-3P,
N-[5-(5-Cyanopyridin-3-ylethynyl)-2-fluorophenyl]-N-
methylsulfonylmethanesulfonamide 866687-26-5P,
[5-(5-Cvanopyridin-3-vlethynyl)-2-fluorophenyl]carbamic acid methyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of pyridines as mGlu5 receptor antagonists)
866684-05-1 HCAPLUS
3-Pvridinecarbonitrile, 5-[2-(2-chlorophenvl)ethvnvl]- (CA INDEX NAME)
```

RN

CN

RN 866684-07-3 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(3-chlorophenyl)ethynyl]- (CA INDEX NAME)

RN 866684-08-4 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(2-fluorophenyl)ethynyl]- (CA INDEX NAME)

RN 866684-10-8 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(3-fluorophenyl)ethynyl]- (CA INDEX NAME)

RN 866684-12-0 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(4-fluorophenyl)ethynyl]- (CA INDEX NAME)

- RN 866684-45-9 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-(4-chlorophenyl)ethynyl]- (CA INDEX NAME)

- RN 866684-85-7 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-(3,4-difluorophenyl)ethynyl]- (CA INDEX NAME)

- RN 866684-87-9 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-(3,5-difluorophenyl)ethynyl]- (CA INDEX NAME)

- RN 866684-88-0 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-(3,4,5-trifluorophenyl)ethynyl]- (CA INDEX NAME)

- RN 866685-08-7 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-(3-chloro-4-fluorophenyl)ethynyl]- (CA INDEX NAME)

RN 866685-14-5 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(5-chloro-2-methoxyphenyl)ethynyl]- (CA INDEX NAME)

RN 866685-16-7 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(3-chloro-4-methoxyphenyl)ethynyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & C & \\ \hline \\ MeO & \\ \hline \\ C1 & CN \\ \end{array}$$

RN 866685-17-8 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(4-fluoro-3-hydroxyphenyl)ethynyl]- (CA INDEX NAME)

RN 866685-19-0 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(4-fluoro-3-methoxyphenyl)ethynyl]- (CA INDEX NAME)

RN 866685-20-3 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-(3-ethoxy-4-fluorophenyl)ethynyl]- (CA INDEX NAME)

RN 866685-22-5 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-[4-fluoro-3-(1-methylethoxy)phenyl]ethynyl]-(CA INDEX NAME)

RN 866685-82-7 HCAPLUS

CN Benzamide, 5-[2-(5-cyano-3-pyridiny1)ethyny1]-2-fluoro- (CA INDEX NAME)

$$\begin{array}{c|c} c & c \\ \hline \\ H_2N-C \\ O \end{array} \quad \begin{array}{c} CN \\ CN \end{array}$$

RN 866685-85-0 HCAPLUS

CN Benzamide, 5-[2-(5-cyano-3-pyridinyl)ethynyl]-2-fluoro-N-methyl- (CA INDEX NAME)

- RN 866685-87-2 HCAPLUS
- CN Benzamide, 5-[2-(5-cyano-3-pyridiny1)ethyny1]-2-fluoro-N, N-dimethy1- (CA INDEX NAME)

$$c = c$$

$$Me_2N - C$$

$$0$$

$$CN$$

- RN 866686-16-0 HCAPLUS
- CN Acetamide, N-[[5-[2-(5-cyano-3-pyridiny1)ethyny1]-2-fluoropheny1]methy1]-(CA INDEX NAME)

- RN 866686-17-1 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-[3-(aminomethyl)-4-fluorophenyl]ethynyl]-(CA INDEX NAME)

$$C = C$$
 H_2N-CH_2
 CN

- RN 866686-20-6 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-[3-[(dimethylamino)methyl]-4fluorophenyl]ethynyl]- (CA INDEX NAME)

RN 866686-22-8 HCAPLUS
CN 3-Pyridinecarbonitrile, 5-[2-[3-(cyanomethyl)-4-fluorophenyl]ethynyl](CA INDEX NAME)

RN 866686-24-0 HCAPLUS

CN Methanesulfonamide, N-[[5-[2-(5-cyano-3-pyridiny1)ethyny1]-2fluoropheny1]methy1]- (CA INDEX NAME)

RN 866686-25-1 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-[3-[[(2-cyanoethy1)methylamino]methyl]-4fluorophenyl]ethynyl]- (CA INDEX NAME)

$$\begin{array}{c} c = c \\ \\ NC - CH_2 - CH_2 - N - CH_2 \\ \\ Me \end{array}$$

RN 866686-27-3 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-[4-fluoro-3-[[methyl(1-methylethyl)amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)

RN 866686-28-4 HCAPLUS CN 3-Pyridinecarbonitrile

3-Pyridinecarbonitrile, 5-[2-[4-fluoro-3-[[(1-methylethyl)amino]methyl]phenyl]ethynyl]- (CA INDEX NAME)

RN 866686-30-8 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-[4-fluoro-3-[(propylamino)methyl]phenyl]ethynyl]- (CA INDEX NAME)

RN 866686-31-9 HCAPLUS

CN 3-Pyridinecarbonitrile, 5-[2-[3-[(ethylamino)methyl]-4-fluorophenyl]ethynyl]- (CA INDEX NAME)

RN 866686-33-1 HCAPLUS

3-Pyridinecarbonitrile, 5-[2-[4-fluoro-3-[(methylamino)methyl]phenyl]ethynyl]- (CA INDEX NAME)

CN

866686-38-6 HCAPLUS RN

Carbamic acid, [[5-[(5-cyano-3-pyridinyl)ethynyl]-2-fluorophenyl]methyl]-, CN ethyl ester (9CI) (CA INDEX NAME)

866686-49-9 HCAPLUS Propanamide, N-[5-[2-(5-cyano-3-pyridinyl)ethynyl]-2-fluorophenyl]-2-CN methyl- (CA INDEX NAME)

866686-52-4 HCAPLUS RN

3-Pyridinecarbonitrile, 5-[2-(4-fluoro-3-nitrophenyl)ethynyl]- (CA INDEX CN NAME)

866687-15-2 HCAPLUS

3-Pyridinecarbonitrile, 5-[2-(3-cyano-4-fluorophenyl)ethynyl]- (CA INDEX CN NAME)

RN 866687-21-0 HCAPLUS

CN Acetamide, N-[5-[2-(5-cyano-3-pyridiny1)ethyny1]-2-fluoropheny1]- (CA INDEX NAME)

RN 866687-23-2 HCAPLUS

CN Methanesulfonamide, N-[5-[2-(5-cyano-3-pyridinyl)ethynyl]-2-fluorophenyl]-(CA INDEX NAME)

RN 866687-24-3 HCAPLUS

CN Methanesulfonamide, N-[5-[2-(5-cyano-3-pyridiny1)ethyny1]-2-fluoropheny1]-N-(methylsulfony1)- (CA INDEX NAME)

RN 866687-26-5 HCAPLUS

CN Carbamic acid, [5-[(5-cyano-3-pyridiny1)ethyny1]-2-fluoropheny1]-, methyl ester (9CI) (CA INDEX NAME)

- IT 866683-64-9P, 5-(3-Chloromethyl-4fluorophenylethynyl)nicotinonitrile 866683-74-1P, 5-(4-Fluoro-3-formylphenylethynyl)nicotinonitrile
 - RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of pyridines as mGlu5 receptor antagonists)
- RN 866683-64-9 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-[3-(chloromethyl)-4-fluorophenyl]ethynyl]-(CA INDEX NAME)

- RN 866683-74-1 HCAPLUS
- CN 3-Pyridinecarbonitrile, 5-[2-(4-fluoro-3-formylphenyl)ethynyl]- (CA INDEX NAME)

REFERENCE COUNT:

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 18:08:42 ON 13 NOV 2008)

FILE 'REGISTRY' ENTERED AT 18:08:51 ON 13 NOV 2008

STRUCTURE UPLOADED

L2 1 S L1 L3 46 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 18:12:39 ON 13 NOV 2008

L4 2 S L3

1 S L4 AND AGEJAS-CHICHARRO, F?/AU

=> s 14 not 15 L6 1 L4 NOT L5

=> s 16 and dressman, b?/au

27 DRESSMAN, B?/AU L7 0 L6 AND DRESSMAN, B?/AU

=> d 16, ibib abs hitstr, 1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:171869 HCAPLUS

DOCUMENT NUMBER: 136:232288

TITLE: Preparation of oxazolidinone chemotherapeutic agents INVENTOR(S): Sciotti, Richard J.; Djuric, Steven W.; Pliushchev,

Marina

PATENT ASSIGNEE(S): Abbott Laboratories, USA SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2002018353	A2	20020307	WO 2001-US26346	20010823		
WO 2002018353	A3	20020613				
W: CA, JP, MX						
RW: AT, BE, CH,	CY, DE	, DK, ES, FI	, FR, GB, GR, IE, IT,	LU, MC, NL,		
PT, SE, TR						
US 6277868	B1	20010821	US 2000-652504	20000831		
US 20020045625	A1	20020418	US 2001-884735	20010619		
US 6410728	B2	20020625				
PRIORITY APPLN. INFO.:			US 2000-652504 I	20000831		
			US 2001-884735 I	20010619		
OTHER SOURCE(S):	MARPAT	136:232288				

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. of the formula I [A=Ph], substituted five-membered aromatic ring containing 1 or 2 atoms selected from N, O, and S and the remaining atoms are carbon, or substituted 6-membered aromatic ring containing 1 or 2 nitrogen atoms

and the remaining atoms are carbon; R1, R2 = independently H, alkyl, cycloalkyl, hydroxy, amino, halo, haloalkyl, and perfluoroalkyl; R3 =

optionally substituted alkyl, alkanoyl, carboxamido, cycloalkyl, cyclothioalkoxy, etc.; R4 = substituted N, O, or S] or therapeutically acceptable salts or prodrugs thereof were prepared Thus, Me 4-((4-(5S)-5-(acetylamino)methyl)-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)ethynyl)benzoate (II) was synthesized in 6 steps from <math display="inline">(5R)-5-(hydroxymethyl)-1,3-oxazolidin-2-one (III). Oxazolidinones of formula I are useful for treating bacterial infections, psoriasis, arthritis, and toxicity due to chemotherapy. Preparation of the compds., compos. containing the compds., and treatment of diseases using the compds. are disclosed.

IT 402960-34-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(asym. synthesis of oxazolidinone chemotherapeutic agents)

RN 402960-34-3 HCAPLUS

CN Acetamide, N-[[(5S)-3-[4-[2-(5-cyano-3-pyridiny1)ethyny1]-3-fluoropheny1]-2-oxo-5-oxazolidiny1]methy1]- (CA INDEX NAME)

Absolute stereochemistry.

=> file caold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	16.28	197.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'CAOLD' ENTERED AT 18:13:40 ON 13 NOV 2008 USE IS SUBJECT TO THE TERMS OF YOUR SIN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERNS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS) FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

 ${\tt CAOLD}$ will be discontinued and removed from associated database clusters.

- . November 22, 2008 removed from database clusters
- . December 31, 2008 removed from STN

Content previously available only in CACLD is now available in CA/CAplus. To learn more about the options available for transferring saved search queries and answer sets to CA/CAplus, contact your SIN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 18:08:42 ON 13 NOV 2008)

FILE 'REGISTRY' ENTERED AT 18:08:51 ON 13 NOV 2008 STRUCTURE UPLOADED

L2 1 S L1 L3 46 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 18:12:39 ON 13 NOV 2008

L4 2 S L3

L5 1 S L4 AND AGEJAS-CHICHARRO, F?/AU L6 1 S L4 NOT L5

L7 0 S L6 AND DRESSMAN, B?/AU

FILE 'CAOLD' ENTERED AT 18:13:40 ON 13 NOV 2008

=> s 13

L8 0 L3